Abstracts tagged "registry and treatment"

Abstract Number: 2206 • 2016 ACR/ARHP Annual Meeting
Data on Treatment from Brazilian Fibromyalgia Patients Registry (EpiFibro)
José E. Martinez^1,2, Marcelo C. Rezende^1,3, Eduardo Paiva^1,4, Daniel Pollak^1,5, Milton Helfenstein Jr^1,6, Jose Roberto Provenza^1,7, Aline Ranzolin^1,8, Luiz Severiano Ribeiro^1,9, Eduardo J. R. Souza^1,10, Roberto E Heymann^1,11 and Marcos Renato Assis^1,12, ¹Brazilian Society of Rheumatology, São Paulo, Brazil, ²Rheumatology, Pontificia Universidade Católica de São Paulo, Sorocaba, Brazil, ³Santa Casa de Campo Grande, Campo Grande, Brazil, ⁴Rheumatology, Universidade Federal do Parana, Curitiba Parana, Brazil, ⁵Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶RUA JOAO DE LACERDA SOARES, 90, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁷Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, ⁸Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ⁹Instituto de Previdência dos Servidores do Estado de Minas Gerais, Belo Horizonte, Brazil, ¹⁰Santa Casa de Belo Horizonte, Belo Horizonte, Brazil, ¹¹Universidade Federal de São Paulo, São Paulo, Brazil, ¹²Rheumatology, Faculdade de Medicina de Marilia, Marilia, Brazil
Background/Purpose: The Brazilian registry on fibromyalgia syndrome (EpiFibro) included 810 patients who satisfied the American College of Rheumatology Classification Criteria for Fibromyalgia (ACR1990) at the…
Abstract Number: 456 • 2015 ACR/ARHP Annual Meeting
Disease and Treatment Characteristics That Might Influence Long-Term Retention with Biologics in the Real-World Clinical Setting: Experience from the Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Institut de Rhumatologie, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Disease and Treatment Characteristics that Might Influence Long-term Retention with Biologics in the Real-world Clinical Setting: Experience from the Rhumadata Clinical Database and Registry Background/Purpose:…
Abstract Number: 2871 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period
Denis Choquette¹, Proton Rahman², Maqbool Sheriff³, Wojciech Olszynski⁴, Emmanouil Rampakakis⁵, Eliofotisti Psaradellis⁶, Francois Nantel⁷, Brendan Osborne⁸, Allen J Lehman⁹, Karina Maslova⁹ and Cathy Tkaczyk⁸, ¹Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada, ⁶JSS Medical Research, Montreal, QC, Canada, ⁷19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ⁸Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Although the efficacy and tolerability of golimumab (GLM) in patients with ankylosing spondylitis (AS) has been demonstrated in several controlled clinical trials, it is…
Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting
Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Jesse Wilkerson², Nastaran Bayat¹, Anna Jansen³, Kathryn Rose⁴, Lukasz Itert⁵, Anne Johnson⁶, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁹, Bob Goldberg¹⁰, Richard Morris⁴, Frederick W. Miller¹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Social and Scientific Systems, Inc., Research Triangle Park, NC, ³Environmental Autoimmunity Group, NIEHS / EAG, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹PRCSG, Cincinnati, OH, ¹⁰The Myositis Association, Alexandria, VA
Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].